171 related articles for article (PubMed ID: 31538250)
1. Selective use of Molecular Testing Based on Sonographic Features of Cytologically Indeterminate Thyroid Nodules: A Decision Analysis.
Zanocco KA; Wang MM; Yeh MW; Livhits MJ
World J Surg; 2020 Feb; 44(2):393-401. PubMed ID: 31538250
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of a novel molecular test for cytologically indeterminate thyroid nodules.
Li H; Robinson KA; Anton B; Saldanha IJ; Ladenson PW
J Clin Endocrinol Metab; 2011 Nov; 96(11):E1719-26. PubMed ID: 21865367
[TBL] [Abstract][Full Text] [Related]
3. ACR TI-RADS and ATA US scores are helpful for the management of thyroid nodules with indeterminate cytology.
Barbosa TLM; Junior COM; Graf H; Cavalvanti T; Trippia MA; da Silveira Ugino RT; de Oliveira GL; Granella VH; de Carvalho GA
BMC Endocr Disord; 2019 Oct; 19(1):112. PubMed ID: 31664992
[TBL] [Abstract][Full Text] [Related]
4. Cost analysis of reflexive versus selective molecular testing for indeterminate thyroid nodules.
Hu QL; Schumm MA; Zanocco KA; Yeh MW; Livhits MJ; Wu JX
Surgery; 2022 Jan; 171(1):147-154. PubMed ID: 34284895
[TBL] [Abstract][Full Text] [Related]
5. Ultrasonography scoring systems can rule out malignancy in cytologically indeterminate thyroid nodules.
Grani G; Lamartina L; Ascoli V; Bosco D; Nardi F; D'Ambrosio F; Rubini A; Giacomelli L; Biffoni M; Filetti S; Durante C; Cantisani V
Endocrine; 2017 Aug; 57(2):256-261. PubMed ID: 27804016
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and prediction of malignancy in cytologically indeterminate thyroid nodules.
Sahin M; Gursoy A; Tutuncu NB; Guvener DN
Clin Endocrinol (Oxf); 2006 Oct; 65(4):514-8. PubMed ID: 16984245
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of lobectomy versus genetic testing (Afirma®) for indeterminate thyroid nodules: Considering the costs of surveillance.
Balentine CJ; Vanness DJ; Schneider DF
Surgery; 2018 Jan; 163(1):88-96. PubMed ID: 29128178
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of molecular testing for cytologically indeterminate thyroid nodules.
Dharampal N; Smith K; Harvey A; Paschke R; Rudmik L; Chandarana S
J Otolaryngol Head Neck Surg; 2022 Dec; 51(1):46. PubMed ID: 36544210
[TBL] [Abstract][Full Text] [Related]
9. Molecular Testing for Thyroid Nodules of Indeterminate Cytology: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2022; 22(2):1-111. PubMed ID: 35591972
[TBL] [Abstract][Full Text] [Related]
10. Indeterminate Single Thyroid Nodule: Synergistic Impact of Mutational Markers and Sonographic Features in Triaging Patients to Appropriate Surgery.
De Napoli L; Bakkar S; Ambrosini CE; Materazzi G; Proietti A; Macerola E; Basolo F; Miccoli P
Thyroid; 2016 Mar; 26(3):390-4. PubMed ID: 26548748
[TBL] [Abstract][Full Text] [Related]
11. Validation of American Thyroid Association Ultrasound Risk Assessment of Thyroid Nodules Selected for Ultrasound Fine-Needle Aspiration.
Tang AL; Falciglia M; Yang H; Mark JR; Steward DL
Thyroid; 2017 Aug; 27(8):1077-1082. PubMed ID: 28657511
[TBL] [Abstract][Full Text] [Related]
12. Ultrasonographic features associated with malignancy in cytologically indeterminate thyroid nodules.
Batawil N; Alkordy T
Eur J Surg Oncol; 2014 Feb; 40(2):182-6. PubMed ID: 24373298
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of immediate biopsy versus surveillance of intermediate-suspicion thyroid nodules.
Kuo EJ; Wu JX; Zanocco KA
Surgery; 2018 Dec; 164(6):1330-1335. PubMed ID: 30055789
[TBL] [Abstract][Full Text] [Related]
14. The diagnostic accuracy of ultrasound-guided fine-needle aspiration biopsy and the sonographic differences between benign and malignant thyroid nodules 3 cm or larger.
Yoon JH; Kwak JY; Moon HJ; Kim MJ; Kim EK
Thyroid; 2011 Sep; 21(9):993-1000. PubMed ID: 21834673
[TBL] [Abstract][Full Text] [Related]
15. Thyroid Nodules with Indeterminate Cytology: Utility of the American Thyroid Association Sonographic Patterns for Cancer Risk Stratification.
Valderrabano P; McGettigan MJ; Lam CA; Khazai L; Thompson ZJ; Chung CH; Centeno BA; McIver B
Thyroid; 2018 Aug; 28(8):1004-1012. PubMed ID: 29848195
[TBL] [Abstract][Full Text] [Related]
16. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
Witt RL
Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
[TBL] [Abstract][Full Text] [Related]
17. Molecular Testing Versus Diagnostic Lobectomy in Bethesda III/IV Thyroid Nodules: A Cost-Effectiveness Analysis.
Nicholson KJ; Roberts MS; McCoy KL; Carty SE; Yip L
Thyroid; 2019 Sep; 29(9):1237-1243. PubMed ID: 31407625
[No Abstract] [Full Text] [Related]
18. Outcomes of Indeterminate Thyroid Nodules Managed Nonoperatively after Molecular Testing.
Zhu CY; Donangelo I; Gupta D; Nguyen DT; Ochoa JE; Yeh MW; Livhits MJ
J Clin Endocrinol Metab; 2021 Mar; 106(3):e1240-e1247. PubMed ID: 33394039
[TBL] [Abstract][Full Text] [Related]
19. Afirma Benign Thyroid Nodules Show Similar Growth to Cytologically Benign Nodules During Follow-Up.
Angell TE; Frates MC; Medici M; Liu X; Kwong N; Cibas ES; Kim MI; Marqusee E
J Clin Endocrinol Metab; 2015 Nov; 100(11):E1477-83. PubMed ID: 26353010
[TBL] [Abstract][Full Text] [Related]
20. Ultrasonography Classification of the American Thyroid Association for Predicting Malignancy in Thyroid Nodules >1cm with Indeterminate Cytology: A Prospective Study.
Rocha TG; Rosario PW; Silva AL; Nunes MB; Silva TH; de Oliveira PHL; Calsolari MR
Horm Metab Res; 2018 Aug; 50(8):597-601. PubMed ID: 30081407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
